Could a common arthritis drug help black patients with kidney disease?
NCT ID NCT05237388
First seen May 08, 2026 · Last updated Jun 19, 2026 · Updated 8 times
Summary
This study tested whether baricitinib, a drug used for arthritis, can safely reduce high protein levels in the urine of African American adults with a specific genetic form of kidney disease (APOL1). Eight participants took the drug to see if it lowered their urine protein and protected kidney function. The goal was to find a new treatment option for this serious condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Research at Pickett Road
Durham, North Carolina, 27705, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.